Board Of Directors

Carlos A. Cabrera  |  Executive Chairman Bio

Carlos A. Cabrera

Carlos joined our board of directors in July 2015 as Executive Chairman. From 1973 to 2009 he was at UOP LLC, now a Honeywell company, serving as Chairman, President and Chief Executive Officer from 2005 to 2009.

Additionally, he served as independent director for Ivanhoe Energy from 2010 to 2015 (and Executive Chairman from 2011 to 2015); independent director for Gevo from 2010 to 2015; and as President and CEO of the National Institute of Clean and Low Carbon Energy from 2009 to 2011.

Carlos holds an MBA from the University of Chicago and a BS in Chemical Engineering from the University of Kentucky.

Christophe Schilling, Ph.D. Bio

Christophe Schilling, Ph.D.

Christophe founded Genomatica in 1998. Since being named CEO in May 2009, he has led Genomatica to widespread recognition as a leader in industrial biotech, with a commercialized first process, top-tier licensees, strong investors - and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Christophe frequently speaks on industry trends at major conferences, and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.

Christophe holds a Ph.D. in bioengineering from the University of California, San Diego. He received a B.S. in biomedical engineering from Duke University and was honored as a Distinguished Young Alumnus in 2010.

William H. Baum Bio

William H. Baum

Bill has served on our board of directors since January 2006, and was Genomatica’s Chief Business Development Officer from September 2010 until April 2014. From August 1997 to September 2010, Bill served in various roles at Diversa Corporation (now known as Verenium Corporation), a biotechnology company focused on the development of biofuels, including Vice President Sales and Marketing from August 1997 to November 1999, Senior Vice President, Business Development from November 1999 to July 2002 and Executive Vice President, Business Development from July 2002 to August 2010. Prior to joining Diversa, Bill served as the Vice President of Global Sales and Marketing at International Specialty Products, Inc., a specialty chemicals company and held a variety of executive positions, both in the United States and internationally, at Betz Laboratories, Inc., a specialty chemicals company. Bill holds a B.S. in Chemistry from Widener University.

Just Jansz Bio

Just joined our board of directors in July 2013. From January 2008 to July 2010, Just was Senior Vice President Technology and President Technology Business for LyondellBasell, and held senior executive roles at Basell from January 2001 to December 2007. Since February 2011, Just has been the founder and director of Expertise Beyond Borders, a global business and technology consultancy for the chemical, process and materials industries. Just holds a Ph.D. in chemical metallurgy and an M.Sc. in mineral engineering from Delft University of Technology in The Netherlands.

Geoff Duyk, M.D., Ph.D. Bio

Geoff joined TPG in 2004 and currently serves as Partner and Managing Director.  Previously, Geoff served on the Board of Directors and was President of Research & Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff and Vice President of Genomics at Millennium Pharmaceuticals.

Geoff has also been an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI).  He graduated from Wesleyan University (1980) with a BA in Biology and was elected to Phi Beta Kappa. He holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr.Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.

Josh Green Bio

Josh has served on our board of directors since July 2007, and as Chairman since January 2013. Mr. Green has been a general partner at Mohr Davidow Ventures since December 2006 with a focus on the clean technologies industry. From August 1995 until October 2003, Josh practiced law at Venture Law Group, and prior to that he practiced law at Brobeck, Phleger & Harrison LLP from September 1980 to August 1995. Josh also serves as a director on several privately held companies in the cleantech and life science spaces. He holds a J.D. from the University of California, Los Angeles School of Law and a B.A. in political science from University of California, Los Angeles.

Thomas J.G. Huot, Ph.D. Bio

Thomas has served on our board of directors since March 2011. He has been a partner at VantagePoint Capital Partners since November 2004, where he currently serves in its CleanTech Practice Group. Previously, he was an analyst with CDP Capital Technology Ventures and before that served as Project Manager for Genopole, a business incubator company specializing in biotechnology companies. Thomas also serves as a director on several privately held companies in the cleantech space. He holds a Ph.D. in Biochemistry and Molecular Biology from University College London and a B.S. in Biochemistry from Université Paris XI, Orsay.

J. Leighton Read, M.D. Bio

Leighton has served on our board of directors since July 2007. From 2001 until 2007, He served as a Managing Member in four funds at Alloy Ventures, where he continues as a Venture Partner. Prior to that, Leighton founded Aviron, a biopharmaceutical company focused on vaccines for infectious disease, where he served as Chairman of the Board and Chief Executive Officer until December 1999 and as a director until its acquisition in January 2002 by MedImmune, Inc. In 1989, he co-founded Affymax NV, a biopharmaceutical company. Leighton currently serves as a director of Alexza Pharmaceuticals, Inc., a pharmaceutical company, and various private companies. He has also previously served as director for a number of other biotechnology companies and on the executive committee of the Biotechnology Industry Association. Leighton holds an M.D. from the University of Texas Health Science Center at San Antonio and completed his training in internal medicine at Duke University and holds a B.S. from Rice University in Psychology and Biology.